SCHEMBL2554521

SCHEMBL2554521

O=CCC1CCC(=O)CC1

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.30
TRIM33 Q9UPN9 1/20 0.30
ESR2 Q92731 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL571633 0.78 NOS3 (0.37)
SCHEMBL13280679 0.78 ESR2 (0.33) ESR2
SCHEMBL28140896 0.78 ALDH1A1 (0.31)
SCHEMBL76463 0.78
SCHEMBL7910058 0.76
SCHEMBL6379288 0.75
SCHEMBL7639721 0.73 TRIM24 (0.37) TRIM24TRIM33ESR2
SCHEMBL826440 0.73
SCHEMBL388985 0.73
SCHEMBL2965185 0.73 TRIM24 (0.37) TRIM24TRIM33ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
US-20110152259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF PALANI ANANDAN 2011-06-23 US disclosed
US-4921994-A ANALGESICS, ANTIEMETICS PFIZER INC. (US) 1990-05-01 US disclosed
US-4831059-A ANTIEMETICS; DIARRHEA; CENTRAL NERVOUS SYSTEM PFIZER INC. (US) 1989-05-16 US disclosed
EP-0048572-B1 SUBSTITUTED 2-HYDROXYPHENYL CYCLOALKANES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. (US) 1987-07-15 EP disclosed
US-4371720-A ANTIDIARRHEALS, ANTIEMETICS PFIZER INC. (US) 1983-02-01 US disclosed
EP-0048572-A2 Substituted 2-hydroxyphenyl cycloalkanes and pharmaceutical compositions thereof PFIZER INC. (US) 1982-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 TRIM24 4745/4885TRIM33 4711/4885ESR2 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.